Measuring the cost of chemotherapy is important, but it is not enough

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 409-410

  Marino, P ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HORMONE RECEPTOR; PACLITAXEL; TAXOID;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; ECONOMIC EVALUATION; EDITORIAL; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MEDICAL DECISION MAKING; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REIMBURSEMENT; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; NEUTROPENIA; PACLITAXEL; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TAXOIDS; THERAPIES, INVESTIGATIONAL;

EID: 40149109481     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn004     Document Type: Editorial

References (20)

1. Gold M, Siegel J, Russell L et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press 1996; 456.
2. Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997; 2(1): 26-30.
3. Weycker D, Malin J, Edelsberg J et al. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008; 19: 454-460.
4. Caggiano V, Weiss RV, Rickert TS et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103(9): 1916-1924.
5. Frampton JE, Faulds D. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 1996; 9(1): 76-96.
6. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 1994; 6(3): 233-239.
7. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96(1): 102-109.
8. Le Corroller AG, Moatti JP. The economic evaluation of hematopoietic growth factors in high-dose chemotherapy. Anticancer Drugs 1998; 9(10): 917-924.
9. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients. Oncologist 2007; 12(4): 478-483.
10. Vu T, Ellard S, Taylor S et al. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Ann Oncol 2008; 19: 461-464.
11. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23(24): 5542-5551.
12. Yee GC. Cost-utility analysis of taxane therapy. Am J Health Syst Pharm 1997; 54(24 Suppl 2): S11-S15.
13. Leung PP, Tannock IF, Oza AM et al. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 1999; 17(10): 3082-3090.
14. Launois R, Reboul-Marty J, Henry B et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996, 10(5): 504-521.
15. Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998; 9(10): 899-907.
16. Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001; 19(11): 1091-1102.
17. Hilf R, Feldstein ML, Gibson SL et al. The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 1980; 45(8): 1993-2000.
18. Spyratos F, Hacene K, Tubiana-Hulin M et al. Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. Eur J Cancer Clin Oncol 1989; 25(8): 1233-1240.
19. Siani C, Moatti J. The handling of uncertainty in economic evaluations of health care strategies. Rev Epidemiol Sante Publique 2003; 51: 255-276.
20. Marino P, Siani C, Roche H et al. Impact of uncertainty on cost-effectiveness analysis of medical strategies: The case of high-dose chemotherapy for breast cancer patients. Int J Technol Assess Health Care 2005; 21(3): 342-350.